杉本　真也 （ スギモト　シンヤ ）

Sugimoto, Shinya

写真a

所属（所属キャンパス）

医学部 内科学教室（消化器） （ 信濃町 ）

職名

助教（有期）
Scopus 論文情報  
総論文数: 96 総引用数: 4949 h-index: 31

Click to view the Scopus page. The data was downloaded from Scopus API inOctober 25, 2026, via http://api.elsevier.com and http://www.scopus.com .

このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 2003年04月
    -
    2009年03月

    慶應義塾大学, 医学部

    大学, 卒業

  • 2014年04月
    -
    2018年03月

    慶應義塾大学, 医学研究科医学研究系専攻

    大学院, 修了, 博士

このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 博士（医学）, 慶應義塾大学, 課程, 2018年03月

    Reconstruction of the Human Colon Epithelium In Vivo

このページの先頭へ▲
 

研究分野 【 表示 ／ 非表示 】

  • ライフサイエンス / 消化器内科学

このページの先頭へ▲

研究キーワード 【 表示 ／ 非表示 】

  • オルガノイド

  • 潰瘍性大腸炎関連腫瘍

  • 炎症性腸疾患

  • 短腸症候群

  • 腸管上皮幹細胞

このページの先頭へ▲
 

著書 【 表示 ／ 非表示 】

  • Organoid derivation and orthotopic xenotransplantation for studying human intestinal stem cell dynamics

    Sugimoto S., Fujii M., Sato T., Methods in Molecular Biology, 2020年

    　概要を見る

    Intestinal stem cells continuously self-renew throughout life to maintain gut homeostasis. With the advent of the organoid culture system, we are now able to indefinitely expand healthy and diseased tissue-derived human intestinal stem cells in vitro and use them for various applications. Nonetheless, investigating the behavior of human intestinal stem cells in vivo still remains challenging. We recently developed an orthotopic xenotransplantation system that realizes in vivo reconstruction of human intestinal epithelial tissue with preserved stem cell hierarchy by engrafting human normal colon organoids onto the mouse colon surface. We also introduced new growth factors, namely, insulin-like growth factor-1 (IGF-1) and fibroblast growth factor-2 (FGF-2), into the culture condition for human intestinal organoids that significantly increase scalability and transfectability of the organoids. By integrating these recent advances, we organized a tissue-oriented platform encompassing derivation of patient-derived intestinal organoids and their orthotopic xenotransplantation. The research platform based on orthotopic xenotransplantation of human intestinal organoids provides a powerful tool for studying human intestinal stem cell biology in native tissue-relevant contexts as well as for establishing novel disease modeling systems.

  • Establishment of 3D intestinal organoid cultures from intestinal stem cells

    Sugimoto S., Sato T., Methods in Molecular Biology, 2017年

    　概要を見る

    The intestinal epithelium is the most rapidly renewed tissue in adult mammals, and its renewal is strictly controlled by intestinal stem cells. Extensive studies using genetic models of intestinal epithelium have revealed the mechanisms underlying the self-renewal of intestinal stem cells. Exploiting this knowledge, we developed a novel 3D culture system that enables the outgrowth of intestinal Lgr5+ stem cells derived from mouse and human tissues into ever-expanding crypt–villus mini-guts, known as intestinal epithelial organoids. These organoids are maintained by the self-renewal of stem cells and give rise to all differentiated cell types of the intestinal epithelium. Once established, organoids can be cryopreserved and thawed when needed. This culture system has been widely used for studying stem cell behavior and gene function and for disease modeling.

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Updated Protocols for 3D and 2D Culture and Histological Analysis of Intestinal Organoids.

    Hanyu H, Sugimoto S, Sato T

    Methods in molecular biology (Clifton, N.J.) 3059   125 - 138 2027年

    ISSN  1064-3745

  • Diagnostic Performance and Reproducibility of Chromoendoscopic Classification (FOCUS Classification: Flat-Type Dysplasia Optical Assessment by Chromoendoscopy in Ulcerative ColitiS) for Flat-Type Dysplasia in Ulcerative Colitis–Associated Neoplasia

    Takabayashi K., Murata S., Sasaki M., Miyazaki K., Masunaga T., Kirita K., Mizutani M., Yoshimatsu Y., Takatori Y., Akimoto T., Kiyohara H., Sugimoto S., Kawasaki S., Mikami Y., Matsuura N., Nakayama A., Sujino T., Ito Y., Yamanoi K., Sekine S., Iwao Y., Yahagi N., Kanai T., Kato M.

    Digestive Endoscopy 38 （ 9 ） e70280 2026年09月

    ISSN  09155635

    　概要を見る

    Objectives: Ulcerative colitis-associated neoplasia (UCAN) often presents as flat-type dysplasia that is difficult to characterize endoscopically. We developed a FOCUS (Flat-type dysplasia Optical assessment by Chromoendoscopy in Ulcerative colitiS) classification and evaluated its diagnostic performance and reproducibility. Methods: This single-center retrospective study included 33 UCAN lesions from 26 patients. Prospectively recorded FOCUS classifications at 230 biopsy sites were compared with histopathology. Chromoendoscopic patterns were categorized as Type I (“suggestive of non-dysplasia,”), Type II (“suggestive of dysplasia with low confidence”), or Type III (“suggestive of dysplasia with high confidence”). Diagnostic performance was assessed using two prespecified thresholds: Types II/III versus Type I and Type III versus Types I/II. Eight endoscopists independently classified all images; interobserver and intraobserver agreement were assessed using Fleiss' and Cohen's κ, respectively. Results: The dysplasia-bearing rate increased stepwise from Type I to Type III (Type I 15.5%, Type II 58.3%, Type III 81.8%). Using the primary threshold, sensitivity was 82.0%, and specificity 75.4% (positive likelihood ratio 3.33; negative likelihood ratio 0.24). Interobserver agreement for the three-category classification was moderate to substantial (Fleiss' κ 0.629; 95% CI 0.545–0.712), and median intraobserver agreement was substantial (Cohen's κ 0.738). Conclusions: The FOCUS classification provides clinically meaningful risk stratification for flat-type dysplasia in a high-risk UCAN cohort, with acceptable interobserver and intraobserver reproducibility.

  • Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease.

    Okada H, Sugimoto S, Kayashima A, Mikami Y, Kanai T, Nakamoto N, Keio PSC–IBD Collaborators

    Journal of gastroenterology 61 （ 7 ） 863 - 879 2026年03月

    ISSN  0944-1174

    　概要を見る

    Primary sclerosing cholangitis (PSC) is frequently accompanied by colitis with clinicopathologic features that differ from conventional inflammatory bowel disease (IBD). Accumulating evidence indicates that PSC-associated IBD (PSC-IBD) often presents as extensive colitis with a right-sided predominant distribution and characteristic endoscopic features, such as rectal sparing and backwash ileitis. Beyond endoscopic appearance, PSC-IBD also appears to have distinct biological underpinnings, including shared genetic susceptibility, dysregulated bile acid signaling, altered gut microbial communities, and immune crosstalk along the gut–liver axis. These mechanisms may contribute not only to intestinal inflammation but also to PSC-related clinical outcomes. From a long-term perspective, patients with PSC and colitis are consistently classified as a high-risk group for colorectal neoplasia, warranting early and intensive colonoscopic surveillance. In parallel, surveillance for hepatobiliary malignancies remains central in PSC care, although risk stratification continues to evolve. Therapeutic management generally follows established IBD algorithms, yet the extent to which colitis-directed therapies modify PSC outcomes remains uncertain, with heterogeneous findings across cohorts and endpoints. In this review, we summarize current knowledge on the clinical phenotype, mechanistic framework, and outcome-driven management of PSC-IBD, and highlight future directions toward precision surveillance and mechanism-based interventions targeting bile acid–microbiota–immune interactions.

  • Evaluation of drug-induced lymphocyte stimulation test in mesalazine-associated allergic drug reaction

    Fukasawa N., Kiyohara H., Adachi T., Sugimoto S., Yoshimatsu Y., Murakami S., Mizushima I., Kaieda Y., Takabayashi K., Tsunoda J., Nakamoto N., Fukunaga K., Taguri M., Mikami Y., Kanai T.

    Journal of Allergy and Clinical Immunology Global 5 （ 2 ） 100625 2026年03月

    　概要を見る

    Background: 5-Aminosalicylic acid (5-ASA) is a fundamental drug for UC management; however, adverse reactions can lead to poor clinical outcomes and increased health care costs. No objective tests currently exist to predict adverse reactions. This study thus investigated 5-ASA across 4 formulations and addressed a key issue in the treatment of mild to moderate ulcerative colitis (UC). Objective: We aimed to examine the utility of the drug-induced lymphocyte stimulation test (DLST) in predicting successful rotation from mesalazine to sulfasalazine (SASP) in patients with UC. Methods: We retrospectively analyzed the largest cohort to date of patients with UC who were suspected of 5-ASA–associated adverse reactions and underwent DLST. We evaluated the DLST positivity rate for the suspected formulation, cross-reactivity to nonsuspected formulations, and clinical outcomes after rotation from mesalazine to SASP. Results: Mesalazine formulations exhibited a DLST positivity rate of 22.0% (18/82), with 45.1% (37/82) of patients testing positive for at least one 5-ASA formulation. Cross-reactivity between mesalazine and SASP was lower at 12.2% (10/82), likely because of structural differences. Adverse reactions typically developed within 2 weeks of initiating 5-ASA and commonly included fever, diarrhea, and bloody stool. Among patients with mesalazine-associated adverse reactions with DLST-negative test result for SASP, 8 of 12 tolerated the rotation. Rotation failure was mainly associated with a positive or borderline DLST result for mesalazine. Conclusions: DLST serves as a useful diagnostic tool for guiding treatment in patients with UC and suspected 5-ASA–associated hypersensitivity reactions. Prospective multicenter studies are needed to validate its clinical utility.

  • Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan.

    Mizushima I, Yoshimatsu Y, Kiyohara H, Sugimoto S, Sujino T, Takabayashi K, Mikami Y, Kanai T

    Intestinal research 2026年02月

    ISSN  1598-9100

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

全件表示 >>

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • 腫瘍構築における分子摂動解析

    2026年06月
    -
    2028年03月

    杉本 真也, 挑戦的研究（萌芽）, 補助金,  研究代表者

  • 小腸機能障害に対する治療的修復アプローチ

    2026年04月
    -
    2029年03月

    日本学術振興会, 科学研究費助成事業, 杉本 真也, 基盤研究(B), 補助金,  研究代表者

  • 細胞固有の組織像から紐解く消化器病学

    2025年10月
    -
    2032年03月

    科学技術振興機構, 戦略的な研究開発の推進 創発的研究支援事業, 杉本 真也, 補助金,  研究代表者

  • 小腸オルガノイドを用いた再生医療へ向けた基盤的研究

    2024年07月
    -
    2027年03月

    国立研究開発法人日本医療研究開発機構, 再生・細胞医療・遺伝子治療実現加速化プログラム, 杉本 真也, 再生・細胞医療・遺伝子治療研究開発課題（基礎応用研究課題）, 補助金,  研究代表者

  • 疾患組織再構築による生体内での腸管病変の可視化

    2024年06月
    -
    2026年03月

    杉本 真也, 挑戦的研究（萌芽）, 補助金,  研究代表者

全件表示 >>

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • 医学生・研修医・専攻医の内科学 ことはじめ2026 指導教官賞

    2026年04月, 第123回日本内科学会講演会

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • 2025年度症例報告最優秀賞専修医部門 指導医

    2026年03月, 慶應大学医学部内科学教室

    受賞区分： 塾内表彰等

  • 第60回日本消化器免疫学会総会奨励賞

    2023年10月

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • 第31回日本医学会総会奨励賞　内科領域

    2023年04月

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • 若手奨励賞

    2022年10月, 第30回日本消化器関連学会週間（JDDW 2022 FUKUOKA）

    受賞区分： 国内学会・会議・シンポジウム等の賞

全件表示 >>

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 内科学（消化器）講義

    2026年度

  • 病態薬物治療学特論

    2026年度

  • 内科学（消化器）講義

    2025年度

  • 内科学（消化器）講義

    2024年度

  • 内科学（消化器）講義

    2023年度

全件表示 >>

このページの先頭へ▲